Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 12/20 | 0.64 |
| ▸ | BRAF | P15056 | 3/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10054909 | 1.00 | NAMPT (0.64) | NAMPTBRAFMAPK14KDRHDAC1 | |
| SCHEMBL2679749 | 1.00 | NAMPT (0.64) | NAMPTBRAFMAPK14KDRHDAC1 | |
| SCHEMBL2679309 | 0.91 | BRAF (0.62) | NAMPTBRAFMAPK14KDRMEN1 | |
| SCHEMBL10078410 | 0.91 | BRAF (0.62) | NAMPTBRAFMAPK14KDRMEN1 | |
| SCHEMBL2678800 | 0.90 | NAMPT (0.55) | NAMPTBRAFMAPK14KDRMEN1 | |
| SCHEMBL10054913 | 0.90 | NAMPT (0.55) | NAMPTBRAFMAPK14KDRMEN1 | |
| SCHEMBL2678798 | 0.90 | NAMPT (0.55) | NAMPTBRAFMAPK14KDRMEN1 | |
| SCHEMBL2680135 | 0.89 | MEN1 (0.52) | NAMPTBRAFMAPK14KDRHDAC1 | |
| SCHEMBL2679264 | 0.89 | MEN1 (0.52) | NAMPTBRAFMAPK14KDRHDAC1 | |
| SCHEMBL10054912 | 0.89 | MEN1 (0.52) | NAMPTBRAFMAPK14KDRHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426446-B2 | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) | 2013-04-23 | — | — | US | claimed |
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD | 2012-05-10 | — | — | US | claimed |
| US-8426446-B2 | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) | 2013-04-23 | — | — | US | disclosed |
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD | 2012-05-10 | — | — | US | disclosed |
| CN-102421754-A | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING JIASHILIANBO PHARM SCI & TECH CO LTD | 2012-04-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | ABL1, ABL2, BCR | NAMPT 3700/4885BRAF 21/4885MAPK14 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.